GlobeNewswire by notified

Press Release: Availability of the Q4 2022 Memorandum for modelling purposes

Share

Availability of the Q4 Memorandum for modelling purposes

Paris, France – January 4, 2023 - Sanofi announced today that its Q4 2022 Memorandum for modelling purposes is available on the "Investors" page of the company's website:

https://www.sanofi.com/en/investors/financial-results-and-events/financial-results/Q4-results-2022

As for each quarter, Sanofi prepared this document to assist in the financial modelling of the Group's quarterly results. This document includes a reminder on various non-comparable items and exclusivity losses as well as the foreign currency impact and share count. Sanofi's fourth-quarter 2022 results will be published on February 3, 2023.

About Sanofi
We are an innovative global healthcare company, driven by one purpose: we chase the miracles of science to improve people’s lives. Our team, across some 100 countries, is dedicated to transforming the practice of medicine by working to turn the impossible into the possible. We provide potentially life-changing treatment options and life-saving vaccine protection to millions of people globally, while putting sustainability and social responsibility at the center of our ambitions.
Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY

Media Relations
Sandrine Guendoul | + 33 6 25 09 14 25 | sandrine.guendoul@sanofi.com
Sally Bain | + 1 617 834 6026 | sally.bain@sanofi.com
Nicolas Obrist | + 33 06 77 21 27 55 | nicolas.obrist@sanofi.com
Victor Rouault | + 33 06 70 93 71 40 | victor.rouault@sanofi.com

Investor Relations
Eva Schaefer-Jansen | + 33 7 86 80 56 39 | eva.schaefer-jansen@sanofi.com
Arnaud Delépine | + 33 06 73 69 36 93 | arnaud.delepine@sanofi.com
Corentine Driancourt | + 33 06 40 56 92 | corentine.driancourt@sanofi.com
Felix Lauscher | + 1 908 612 7239 | felix.lauscher@sanofi.com
Priya Nanduri | + 1 617 764 6418 | priya.nanduri@sanofi.com

Nathalie Pham | + 33 07 85 93 30 17 | nathalie.pham@sanofi.com

Sanofi Forward-Looking Statements
This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words “expects”, “anticipates”, “believes”, “intends”, “estimates”, “plans” and similar expressions. Although Sanofi’s management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, the fact that product candidates if approved may not be commercially successful, the future approval and commercial success of therapeutic alternatives, Sanofi’s ability to benefit from external growth opportunities, to complete related transactions and/or obtain regulatory clearances, risks associated with intellectual property and any related pending or future litigation and the  ultimate outcome of such litigation, trends in exchange rates and prevailing interest rates, volatile economic and market conditions, cost containment initiatives and subsequent changes thereto, and the impact that COVID-19 will have on us, our customers, suppliers, vendors, and other business partners, and the financial condition of any one of them, as well as on our employees and on the global economy as a whole. Any material effect of COVID-19 on any of the foregoing could also adversely impact us. This situation is changing rapidly and additional impacts may arise of which we are not currently aware and may exacerbate other previously identified risks. The risks and uncertainties also include the uncertainties discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under “Risk Factors” and “Cautionary Statement Regarding Forward-Looking Statements” in Sanofi’s annual report on Form 20-F for the year ended December 31, 2021. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.

Attachment

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

ULTRA Abu Dhabi Drops Stacked Phase One Lineup31.1.2023 23:00:00 CET | Press release

AFROJACK, CALVIN HARRIS, ILLENIUM, NERVO, NGHTMRE, SKRILLEX to headline the Main Stage. ADAM BEYER, AMELIE LENS, SASHA & JOHN DIGWEED to lead Resistance. ULTRA Abu Dhabi to be held at ETIHAD PARK, YAS ISLAND, ABU DHABI on SATURDAY 4 & SUNDAY 5 MARCH 2023. SEOUL, South Korea, Jan. 31, 2023 (GLOBE NEWSWIRE) -- UC Global, the regional partner of ULTRA Worldwide in the United Arab Emirates and the local organizer of ULTRA Abu Dhabi, has announced the first wave of headliners set to play its inaugural edition Saturday 4 and Sunday 5 March 2023. Ever since the announcement that ULTRA Worldwide would be headed to the Middle East for the very first time, anticipation has reached a fever pitch as to which artists would be coming to the region. Now, the wait is finally over as the festival's stellar Phase One lineup has been revealed. Multi-award-winning and platinum-record-selling artist Afrojack is no stranger to the ULTRA main stage and will be on hand to deliver yet another high-octane set.

LumiraDx Announces Commercial Shipment of its Point of Care NT-proBNP Test in Europe, Supporting Heart Health Checks in UK31.1.2023 22:30:00 CET | Press release

Run on the highly portable LumiraDx Platform, the LumiraDx NT-proBNP test is a quantitative, fingerstick blood assay designed for near-patient testing with lab-comparable results in 12 minutes. It is the only fingerstick NT-proBNP test currently commercially available.The LumiraDx NT-proBNP test is a rapid microfluidic immunofluorescence assay that can aid in the diagnosis of congestive heart failure (CHF).Available on the same point of care (POC) Platform as LumiraDx’s high sensitivity SARS-CoV-2 antigen, HbA1c, D-Dimer, INR, CRP, Flu A/B, RSV, SARS-CoV-2 antibody, SARS-CoV-2 antigen pool, SARS-CoV-2 Ag Ultra and Ultra Pool tests.*LumiraDx is partnering with Medtronic and a number of local healthcare trusts and charities in the UK to launch the Your Heart Matters Bus initiative where members of the public will be offered free heart health checks, LumiraDx NT-proBNP test results as indicated and medical information through a mobile walk-on service. LONDON, Jan. 31, 2023 (GLOBE NEWSWIRE

International Petroleum Corporation Updated Share Capital31.1.2023 21:30:00 CET | Press release

International Petroleum Corporation (IPC or the Corporation) (TSX, Nasdaq Stockholm: IPCO)reports the following, in accordance with the Swedish Financial Instruments Trading Act: Following the cancellation of738,243 common shares repurchased by IPC under the share repurchase program,the total number of issued and outstanding common shares of the Corporation is 136,089,756 common shares with voting rights as atJanuary 31, 2023, of which IPC holds71,416 common shares in treasury. International Petroleum Corp. (IPC) is an international oil and gas exploration and production company with a high quality portfolio of assets located in Canada, Malaysia and France, providing a solid foundation for organic and inorganic growth. IPC is a member of the Lundin Group of Companies. IPC is incorporated in Canada and IPC’s shares are listed on the Toronto Stock Exchange (TSX) and the Nasdaq Stockholm exchange under the symbol "IPCO". For further information, please contact: Rebecca Gordon VP Corporate

Nokia Corporation: Repurchase of own shares on 31.01.202331.1.2023 20:00:00 CET | Press release

Nokia Corporation Stock Exchange Release 31 January 2023 at 21:00 EET Nokia Corporation: Repurchase of own shares on 31.01.2023 Espoo, Finland – On 31 January 2023 Nokia Corporation (LEI: 549300A0JPRWG1KI7U06) has acquired its own shares (ISIN FI0009000681) as follows: Trading venue (MIC Code)Number of sharesWeighted average price / share, EUR*XHEL261,4854.33CEUX19,9384.34AQEU23,7644.33TQEX12,8134.34Total318,0004.33 * Rounded to two decimals On 3 February 2022, Nokia announced that its Board of Directors is initiating a share buyback program under the authorization granted by Nokia’s Annual General Meeting on 8 April 2021 to return up to EUR 600 million of cash to shareholders in tranches over a period of two years. The second phase of the share buyback program in compliance with the Market Abuse Regulation (EU) 596/2014 (MAR), the Commission Delegated Regulation (EU) 2016/1052 and under the authorization granted by Nokia’s Annual General Meeting on 5 April 2022 started on 2 January 20